Subscribe to NRx Newsletter

depression

NRx Pharmaceuticals Builds on Its Intellectual Property Foundation for Neuropsychiatric Conditions – Adds New U.S. Patent to Portfolio

NRx Pharmaceuticals, Inc. today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 11,576,911. This patent, issued to Glytech LLC, is exclusively licensed to NeuroRx, Inc., a wholly owned subsidiary of NRx, under the terms of a license agreement with Glytech through which NeuroRx has the sole rights to this and other patents, both U.S. and international.